These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 36946603)

  • 1. Targeting amyloid β in Alzheimer's disease: Meta-analysis of low-dose solanezumab in Alzheimer's disease with mild dementia studies.
    Holdridge KC; Yaari R; Hoban DB; Andersen S; Sims JR
    Alzheimers Dement; 2023 Oct; 19(10):4619-4628. PubMed ID: 36946603
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase 3 solanezumab trials: Secondary outcomes in mild Alzheimer's disease patients.
    Siemers ER; Sundell KL; Carlson C; Case M; Sethuraman G; Liu-Seifert H; Dowsett SA; Pontecorvo MJ; Dean RA; Demattos R
    Alzheimers Dement; 2016 Feb; 12(2):110-120. PubMed ID: 26238576
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Magnetic resonance imaging measures of brain volumes across the EXPEDITION trials in mild and moderate Alzheimer's disease dementia.
    Svaldi DO; Higgins IA; Holdridge KC; Yaari R; Case M; Bracoud L; Scott D; Shcherbinin S; Sims JR
    Alzheimers Dement (N Y); 2022; 8(1):e12313. PubMed ID: 35783453
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trial of Solanezumab for Mild Dementia Due to Alzheimer's Disease.
    Honig LS; Vellas B; Woodward M; Boada M; Bullock R; Borrie M; Hager K; Andreasen N; Scarpini E; Liu-Seifert H; Case M; Dean RA; Hake A; Sundell K; Poole Hoffmann V; Carlson C; Khanna R; Mintun M; DeMattos R; Selzler KJ; Siemers E
    N Engl J Med; 2018 Jan; 378(4):321-330. PubMed ID: 29365294
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease.
    Doody RS; Thomas RG; Farlow M; Iwatsubo T; Vellas B; Joffe S; Kieburtz K; Raman R; Sun X; Aisen PS; Siemers E; Liu-Seifert H; Mohs R; ;
    N Engl J Med; 2014 Jan; 370(4):311-21. PubMed ID: 24450890
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Utilization of Observational Data as a Proxy Cohort for Comparison Purposes with Open-Label Study Results: An Example from Alzheimer's Disease.
    Reed C; Happich M; Raskin J; Tockhorn-Heidenreich A; Belger M
    J Prev Alzheimers Dis; 2019; 6(2):90-99. PubMed ID: 30756115
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trial of Solanezumab in Preclinical Alzheimer's Disease.
    Sperling RA; Donohue MC; Raman R; Rafii MS; Johnson K; Masters CL; van Dyck CH; Iwatsubo T; Marshall GA; Yaari R; Mancini M; Holdridge KC; Case M; Sims JR; Aisen PS;
    N Engl J Med; 2023 Sep; 389(12):1096-1107. PubMed ID: 37458272
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Grasping at straws: the failure of solanezumab to modify mild Alzheimer's disease.
    Doggrell SA
    Expert Opin Biol Ther; 2018 Dec; 18(12):1189-1192. PubMed ID: 30376649
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantile regression to characterize solanezumab effects in Alzheimer's disease trials.
    Chen YF; Ma X; Sundell K; Alaka K; Schuh K; Raskin J; Dean RA
    Alzheimers Dement (N Y); 2016 Sep; 2(3):192-198. PubMed ID: 29067306
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody.
    Swanson CJ; Zhang Y; Dhadda S; Wang J; Kaplow J; Lai RYK; Lannfelt L; Bradley H; Rabe M; Koyama A; Reyderman L; Berry DA; Berry S; Gordon R; Kramer LD; Cummings JL
    Alzheimers Res Ther; 2021 Apr; 13(1):80. PubMed ID: 33865446
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Delayed-start analysis: Mild Alzheimer's disease patients in solanezumab trials, 3.5 years.
    Liu-Seifert H; Siemers E; Holdridge KC; Andersen SW; Lipkovich I; Carlson C; Sethuraman G; Hoog S; Hayduk R; Doody R; Aisen P
    Alzheimers Dement (N Y); 2015 Sep; 1(2):111-121. PubMed ID: 29854931
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cognitive Impairment Precedes and Predicts Functional Impairment in Mild Alzheimer's Disease.
    Liu-Seifert H; Siemers E; Price K; Han B; Selzler KJ; Henley D; Sundell K; Aisen P; Cummings J; Raskin J; Mohs R;
    J Alzheimers Dis; 2015; 47(1):205-14. PubMed ID: 26402769
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cognitive and functional decline and their relationship in patients with mild Alzheimer's dementia.
    Liu-Seifert H; Siemers E; Sundell K; Price K; Han B; Selzler K; Aisen P; Cummings J; Raskin J; Mohs R
    J Alzheimers Dis; 2015; 43(3):949-55. PubMed ID: 25125457
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Amyloid-related imaging abnormalities from trials of solanezumab for Alzheimer's disease.
    Carlson C; Siemers E; Hake A; Case M; Hayduk R; Suhy J; Oh J; Barakos J
    Alzheimers Dement (Amst); 2016; 2():75-85. PubMed ID: 27239538
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Souvenaid for Alzheimer's disease.
    Burckhardt M; Watzke S; Wienke A; Langer G; Fink A
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD011679. PubMed ID: 33320335
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Amyloid-directed monoclonal antibodies for the treatment of Alzheimer's disease: the point of no return?
    Panza F; Solfrizzi V; Imbimbo BP; Logroscino G
    Expert Opin Biol Ther; 2014 Oct; 14(10):1465-76. PubMed ID: 24981190
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Central pharmacodynamic activity of solanezumab in mild Alzheimer's disease dementia.
    Willis BA; Sundell K; Lachno DR; Ferguson-Sells LR; Case MG; Holdridge K; DeMattos RB; Raskin J; Siemers ER; Dean RA
    Alzheimers Dement (N Y); 2018; 4():652-660. PubMed ID: 30511011
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimer's disease (BLAZE).
    Salloway S; Honigberg LA; Cho W; Ward M; Friesenhahn M; Brunstein F; Quartino A; Clayton D; Mortensen D; Bittner T; Ho C; Rabe C; Schauer SP; Wildsmith KR; Fuji RN; Suliman S; Reiman EM; Chen K; Paul R
    Alzheimers Res Ther; 2018 Sep; 10(1):96. PubMed ID: 30231896
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer's disease.
    Salloway S; Farlow M; McDade E; Clifford DB; Wang G; Llibre-Guerra JJ; Hitchcock JM; Mills SL; Santacruz AM; Aschenbrenner AJ; Hassenstab J; Benzinger TLS; Gordon BA; Fagan AM; Coalier KA; Cruchaga C; Goate AA; Perrin RJ; Xiong C; Li Y; Morris JC; Snider BJ; Mummery C; Surti GM; Hannequin D; Wallon D; Berman SB; Lah JJ; Jimenez-Velazquez IZ; Roberson ED; van Dyck CH; Honig LS; Sánchez-Valle R; Brooks WS; Gauthier S; Galasko DR; Masters CL; Brosch JR; Hsiung GR; Jayadev S; Formaglio M; Masellis M; Clarnette R; Pariente J; Dubois B; Pasquier F; Jack CR; Koeppe R; Snyder PJ; Aisen PS; Thomas RG; Berry SM; Wendelberger BA; Andersen SW; Holdridge KC; Mintun MA; Yaari R; Sims JR; Baudler M; Delmar P; Doody RS; Fontoura P; Giacobino C; Kerchner GA; Bateman RJ;
    Nat Med; 2021 Jul; 27(7):1187-1196. PubMed ID: 34155411
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of monoclonal antibodies against amyloid-β on clinical and biomarker outcomes and adverse event risks: A systematic review and meta-analysis of phase III RCTs in Alzheimer's disease.
    Avgerinos KI; Ferrucci L; Kapogiannis D
    Ageing Res Rev; 2021 Jul; 68():101339. PubMed ID: 33831607
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.